Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.84), $0.08 worse than the analyst estimate of ($0.76). Revenue for the quarter came in at $59 thousand versus the consensus estimate of $40 thousand.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.